Skip to NavigationSkip to content


Oral contraceptive use as teenager linked to depression as an adult, study says

Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a study published in The Journal of Child Psychology and Psychiatry.

In a study of 1,236 women from the United States, researchers from the University of British Columbia found that women who had either never used oral contraceptives or had only started using them as an adult were less likely to experience major depressive disorder (MDD) than those women who had used oral contraceptives during adolescence.

Sunovion CMO Dr Antony Loebel made company's new CEO

Published on: 05/03/19

Japanese drugmaker Sunovion Pharmaceuticals has made their current Chief Medical Officer (CMO) the company’s new Chief Executive Officer (CEO). Dr Antony Loebel will succeed Nobuhiko Tamura who has headed the company since 2014.

Nerve stimulation treatments improve quality of life in depressed people, study shows

Image Credit: Manu5

Nerve stimulation treatments can significantly improve depressed people’s quality of life, even in cases in which an individual continues to suffer from depression, according to a study led by researchers at Washington University School of Medicine in St Louis.

The study saw Washington University researchers test vagus nerve stimulation (VNS) treatment, which was approved by the FDA in 2005, on a group of 328 patients suffering from cases of depression in which four or more antidepressants had failed to work effectively.

Mental health crisis as UK struggles with number of psychiatrists

Research undertaken by the Royal College of Psychiatrists using data from NHS Digital has found that the number of psychiatrists available to people varies wildly by geographical location. Overall numbers of psychiatrists were also found to be low across the country, with levels of consultants England rising by only 1.7% over the past five years.

Boehringer launches psychiatric research project

boehringer iamge

Boehringer Ingelheim has announced it will collaborate on a new three-year programme to investigate the neural foundations of psychiatric disorders. 

Research will be conducted with Californian firm Circuit Therapeutics, whose recently-developed neuromodulation technology - optogenetics - facilitates the monitoring and control of nerve cells and circuits in the brain. 

CNS Orphan Diseases- the alternative route in CNS

Advances in Neuropsychiatric Treatment

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches